Icecure Medical Financials
ICCM Stock | USD 0.83 0.04 5.06% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 4.95 | 3.6642 |
|
|
The financial analysis of Icecure Medical is a critical element in measuring its lifeblood. Investors should not minimize Icecure Medical's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Icecure | Select Account or Indicator |
Understanding current and past Icecure Medical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Icecure Medical's financial statements are interrelated, with each one affecting the others. For example, an increase in Icecure Medical's assets may result in an increase in income on the income statement.
Icecure Medical Stock Summary
Icecure Medical competes with BrainsWay, SurModics, STRATA Skin, Tenon Medical, and Brainsway. IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation of tumors in the human body. The company was incorporated in 2006 and is headquartered in Caesarea, Israel. Icecure Medical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 55 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | IL0011224156 |
CUSIP | M53071136 |
Location | Israel |
Business Address | 7 HaEshel Street, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.icecure-medical.com |
Phone | 972 4 623 0333 |
Currency | USD - US Dollar |
Icecure Medical Key Financial Ratios
Return On Equity | -0.94 | ||||
Operating Margin | (3.19) % | ||||
Price To Sales | 13.08 X | ||||
Revenue | 3.23 M | ||||
Gross Profit | 1.45 M |
Icecure Medical Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.3M | 10.3M | 32.3M | 30.2M | 16.4M | 12.7M | |
Other Current Liab | 1.1M | 3.1M | 2.0M | 2.8M | 3.0M | 1.8M | |
Net Debt | (5.5M) | (3.2M) | (24.7M) | (23.1M) | (9.9M) | (10.4M) | |
Retained Earnings | (48.5M) | (57.0M) | (58.4M) | (75.4M) | (90.1M) | (85.6M) | |
Accounts Payable | 425.7K | 645K | 881K | 714K | 502K | 452.6K | |
Cash | 5.8M | 3.5M | 25.6M | 23.7M | 10.5M | 9.3M | |
Net Receivables | 104.8K | 165K | 771K | 366K | 103K | 108.2K | |
Inventory | 717.3K | 1.1M | 2.0M | 2.9M | 2.3M | 1.2M | |
Other Current Assets | 301.1K | 5.0M | 2.0M | 1.2M | 965K | 1.4M | |
Total Liab | 4.7M | 5.8M | 5.3M | 4.8M | 4.2M | 3.6M | |
Total Current Assets | 6.9M | 9.7M | 30.3M | 28.1M | 14.2M | 11.8M | |
Common Stock | 1.3M | 2.7M | 3.5M | 5.0M | 5.8M | 6.1M | |
Other Assets | 139K | 118K | 333K | 34K | 39.1K | 37.1K | |
Other Liab | 2.7M | 3.3M | 5.7M | 618K | 556.2K | 528.4K | |
Net Tangible Assets | 9.1M | 14.7M | 27.0M | 25.4M | 29.2M | 16.1M | |
Net Invested Capital | 9.1M | 14.7M | 27.0M | 25.4M | 12.2M | 16.3M | |
Net Working Capital | 11.3M | 18.6M | 26.3M | 23.8M | 10.3M | 16.7M |
Icecure Medical Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 22.8K | 31.7K | 171K | 239K | 215.1K | 120.2K | |
Total Revenue | 1.7M | 4.1M | 4.1M | 3.1M | 3.2M | 2.1M | |
Gross Profit | 576.4K | 2.7M | 2.2M | 1.4M | 1.3M | 957.4K | |
Operating Income | (4.6M) | (4.4M) | (9.7M) | (16.7M) | (15.6M) | (14.8M) | |
Ebit | (4.6M) | (4.1M) | (9.7M) | (16.7M) | (15.6M) | (14.8M) | |
Research Development | 2.8M | 4.1M | 5.9M | 9.1M | 8.3M | 8.7M | |
Ebitda | (4.6M) | (4.1M) | (9.6M) | (16.5M) | (15.3M) | (14.5M) | |
Cost Of Revenue | 1.1M | 1.4M | 1.9M | 1.6M | 1.9M | 1.1M | |
Income Before Tax | (4.8M) | (4.7M) | (9.9M) | (17.0M) | (14.7M) | (13.9M) | |
Net Income | (4.8M) | (4.8M) | (10.1M) | (17.2M) | (14.7M) | (13.9M) | |
Income Tax Expense | (13.6K) | 86.8K | 171K | 239K | 155.1K | 162.9K | |
Net Interest Income | (698K) | (880K) | (171K) | (239K) | 924K | 970.2K |
Icecure Medical Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (6.9K) | (369.8K) | (891K) | (902K) | 582K | 611.1K | |
Change In Cash | 1.2M | (2.7M) | 22.1M | (2.0M) | (13.1M) | (12.5M) | |
Free Cash Flow | (1.8M) | (4.0M) | (13.1M) | (15.2M) | (13.0M) | (12.4M) | |
Depreciation | 155.4K | 266.2K | 127K | 248K | 323K | 339.2K | |
Other Non Cash Items | (59.5K) | 310.1K | 5K | 359K | (25K) | (23.8K) | |
Capital Expenditures | 102.2K | 237.9K | 533K | 891K | 480K | 246.6K | |
Net Income | (4.8M) | (4.7M) | (9.9M) | (17.0M) | (14.7M) | (13.9M) | |
End Period Cash Flow | 5.8M | 3.5M | 25.6M | 23.7M | 10.5M | 9.0M | |
Change To Netincome | 1.4M | 1.1M | 1.8M | 321K | 288.9K | 274.5K |
Icecure Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Icecure Medical's current stock value. Our valuation model uses many indicators to compare Icecure Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Icecure Medical competition to find correlations between indicators driving Icecure Medical's intrinsic value. More Info.Icecure Medical is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Icecure Medical's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Icecure Medical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Icecure Medical Systematic Risk
Icecure Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Icecure Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was four with a total number of output elements of fifty-seven. The Beta measures systematic risk based on how returns on Icecure Medical correlated with the market. If Beta is less than 0 Icecure Medical generally moves in the opposite direction as compared to the market. If Icecure Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Icecure Medical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Icecure Medical is generally in the same direction as the market. If Beta > 1 Icecure Medical moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Icecure Medical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Icecure Medical's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Icecure Medical growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Icecure Medical November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Icecure Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Icecure Medical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Icecure Medical based on widely used predictive technical indicators. In general, we focus on analyzing Icecure Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Icecure Medical's daily price indicators and compare them against related drivers.
Downside Deviation | 4.42 | |||
Information Ratio | 0.0393 | |||
Maximum Drawdown | 30.34 | |||
Value At Risk | (6.90) | |||
Potential Upside | 9.86 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Icecure Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Icecure Stock, please use our How to Invest in Icecure Medical guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Icecure Medical. If investors know Icecure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Icecure Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 0.071 | Quarterly Revenue Growth 0.079 | Return On Assets (0.47) | Return On Equity (0.94) |
The market value of Icecure Medical is measured differently than its book value, which is the value of Icecure that is recorded on the company's balance sheet. Investors also form their own opinion of Icecure Medical's value that differs from its market value or its book value, called intrinsic value, which is Icecure Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Icecure Medical's market value can be influenced by many factors that don't directly affect Icecure Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Icecure Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Icecure Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Icecure Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.